Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757484

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757484

Curative Therapeutics

PUBLISHED:
PAGES: 390 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Global Curative Therapeutics Market to Reach US$655.1 Million by 2030

The global market for Curative Therapeutics estimated at US$474.0 Million in the year 2024, is expected to reach US$655.1 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Biology Modifying Drugs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$436.6 Million by the end of the analysis period. Growth in the Gene Therapies segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$129.1 Million While China is Forecast to Grow at 8.8% CAGR

The Curative Therapeutics market in the U.S. is estimated at US$129.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$132.2 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Curative Therapeutics Market - Key Trends & Drivers Summarized

What Defines Curative Therapeutics and Why Are They Reshaping Modern Healthcare?

Curative therapeutics refer to treatments or interventions that aim to eliminate the root cause of a disease rather than merely managing symptoms or slowing progression. Unlike traditional chronic disease management approaches, curative therapies offer the potential for complete restoration of health-often through surgical correction, cell or gene modification, or pathogen eradication. These treatments are particularly transformative in areas such as genetic disorders, oncology, infectious diseases, and rare metabolic conditions.

This shift from maintenance to cure is gaining prominence in the global healthcare agenda, fueled by scientific breakthroughs in molecular medicine, regenerative therapies, and precision drug targeting. Advances in genomic editing, stem cell biology, and immunotherapy have enabled the development of curative options for diseases previously considered untreatable. As healthcare systems increasingly prioritize long-term outcomes and cost-effectiveness, curative therapeutics are seen as a powerful tool to reduce lifetime healthcare expenditures, improve quality of life, and potentially eradicate certain disease burdens altogether.

How Are Technology Platforms and Modalities Powering the Rise of Curative Therapies?

The evolution of curative therapeutics is closely tied to innovation in biologics, gene editing platforms, and personalized medicine. One of the most prominent developments has been in gene therapies, where techniques like CRISPR/Cas9 and viral vector delivery systems are enabling permanent correction of disease-causing mutations. Approved gene therapies for conditions like spinal muscular atrophy or inherited retinal diseases have validated this approach and set the stage for broader application in hemophilia, beta-thalassemia, and immune deficiencies.

Cell-based therapies, particularly those involving autologous or allogeneic stem cells, are gaining traction for regenerative applications in hematologic malignancies, neurodegenerative diseases, and cardiac repair. Meanwhile, immunotherapies such as CAR-T cell treatments have demonstrated curative potential in certain lymphomas and leukemias by reprogramming the patient’s immune system to eliminate cancer. Additionally, breakthroughs in small-molecule antivirals and antimicrobial agents are offering curative regimens for chronic infectious diseases like hepatitis C, with shorter treatment durations and durable response rates.

Which Therapeutic Areas and Patient Segments Are Driving Adoption?

The most significant impact of curative therapeutics is being observed in rare diseases and genetic disorders, where a one-time intervention can replace a lifetime of symptomatic management. Pediatric patients with inherited conditions are prime candidates, as early intervention can significantly alter disease trajectory. Similarly, curative intent is increasingly targeted in oncology, where certain cancers are being approached with multimodal strategies combining surgery, immunotherapy, and targeted agents aimed at complete remission or eradication.

Infectious disease management is another key domain, especially for chronic viral infections where curative drug regimens are being prioritized in global elimination strategies. In parallel, chronic disease categories such as diabetes or heart failure are witnessing early-stage investigations into regenerative and cell-based therapies with the potential for disease reversal. Patients in high-risk or refractory categories, where conventional treatments have failed, represent a major portion of the early adoption base for curative therapeutic trials and approvals.

What Factors Are Driving Market Growth for Curative Therapeutics Globally?

The growth in the curative therapeutics market is driven by several factors tied to scientific innovation, unmet medical needs, and long-term healthcare economics. Increasing investment in advanced biologics, gene editing platforms, and cellular therapies is accelerating the pipeline of curative candidates across multiple disease areas. The high clinical and economic burden of chronic, lifelong diseases is creating urgency among payers and regulators to support curative models that offer durable relief and cost offset over time.

Strong regulatory momentum-including expedited pathways for breakthrough therapies, orphan drug status, and priority reviews-is enabling faster approvals and incentivizing R&D in curative domains. Rising global awareness and advocacy around rare and genetic diseases are increasing trial enrollment and early diagnosis, allowing timely deployment of curative interventions. Lastly, precision medicine approaches powered by biomarkers and companion diagnostics are ensuring that these therapies are effectively targeted, maximizing therapeutic success. Collectively, these drivers are fueling a transformative shift in healthcare delivery, where curative outcomes are no longer aspirational but increasingly achievable.

SCOPE OF STUDY:

The report analyzes the Curative Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies); Indication (Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication, Other Indications); End-Use (Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Alnylam Pharmaceuticals
  • Beam Therapeutics
  • Bluebird bio
  • Cartesian Therapeutics
  • CRISPR Therapeutics
  • Curative Biotechnology
  • CureAge Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Intellia Therapeutics
  • Jnana Therapeutics
  • Kymera Therapeutics
  • MiNA Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics
  • Seagen Inc.
  • Spark Therapeutics
  • Vertex Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Product Code: MCP36644

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Curative Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic and Rare Diseases Propels Growth in Curative Therapeutics R&D
    • Breakthroughs in Cell and Gene Therapy Strengthen Business Case for One-Time, Curative Treatments
    • Regulatory Acceleration for Orphan Drug Approvals Throws the Spotlight on Fast-Tracked Therapies
    • Shift from Maintenance Drugs to Functional Cures Drives Strategic Investment in Biotech Pipelines
    • Precision Medicine Advancements Fuel Personalized Curative Treatment Modalities
    • Growing Payer Willingness to Support High-Value, Long-Term Cure Models Sustains Market Adoption
    • Expansion of Clinical Trials in Genetic Disorders Accelerates Curative Therapy Commercialization
    • Emergence of Regenerative Therapies in Musculoskeletal and Neurological Diseases Drives Pipeline Diversification
    • Focus on Rare Pediatric Diseases Strengthens Public-Private Research Collaborations
    • Investment Surge in mRNA and CRISPR-Based Curative Platforms Opens New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Curative Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Curative Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biology Modifying Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biology Modifying Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biology Modifying Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cell Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Musculoskeletal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Musculoskeletal Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurodegenerative Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurodegenerative Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Rare Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Rare Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Rare Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hepatitis C Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hepatitis C Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hepatitis C Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • JAPAN
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • CHINA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • EUROPE
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Curative Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • FRANCE
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • GERMANY
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Curative Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • INDIA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Curative Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Curative Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • AFRICA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!